OpenAlex
PricingAboutJobs
Log inGet started
Work

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials

HTML

Year: 2014
Type: article
Study design: Clinical Trial
Source: The Lancet Respiratory Medicine
DOI: 10.1016/s2213-2600(14)70065-7
Authors: Marc Decramer, Antonio Anzueto, Edward Kerwin, Thomas Kaelin, Nathalie Richard, Glenn Crater, Maggie Tabberer, Stephanie Harris, Alison Church
Institutions: Universitair Ziekenhuis Leuven, KU Leuven, The University of Texas at San Antonio Health Science Center, South Texas Veterans Health Care System, GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom)
Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: umeclidinium, vilanterol, tiotropium, chronic obstructive pulmonary disease, long-acting bronchodilators, combination therapy, FEV1, lung function, adverse events, dry powder inhaler, HandiHaler, Ellipta, COPD exacerbations, COPD hospitalization, COPD mortality, COPD-related emergency department visits
SDG: Good health and well-being

Open Access status: closed

Funder: GlaxoSmithKline
OpenAlex ID: W2026585673
FWCI: 32.96
Cites: 33
Cited by: 244
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security